Cannabis

Cannabis

Known Therapeutic Benefits From Medicinal Cannabinoids

(Known Therapeutic Benefits From Medicinal Cannabinoids) "Cannabis preparations exert numerous therapeutic effects. They have antispastic, analgesic, antiemetic, neuroprotective, and anti-inflammatory actions, and are effective against certain psychiatric diseases. Currently, however, only one cannabis extract is approved for use. It contains THC and CBD [cannabidiol] in a 1:1 ratio and was licensed in 2011 for treatment of moderate to severe refractory spasticity in multiple sclerosis (MS).

Comparison of Results from Standardized Field Sobriety Tests (SFST) and Roadside Saliva Drug Tests in Detecting Cannabis Use

(Comparison of Results from Standardized Field Sobriety Tests (SFST) and Roadside Saliva Drug Tests in Detecting Cannabis Use) "The SFST was mildly sensitive to the effects of cannabis alone. A dose of 400 ?g/kg body weight THC significantly increased the percentage of participants displaying impairments in OLS compared to baseline performance from 21 to 50 %. THC also increased percentage of individuals showing impairment on HGN from 0 to 15 %, relative to baseline, but this change only approached statistical significance.

Comparison of Results from Standardized Field Sobriety Tests (SFST) and Roadside Drug Testing

(Comparison of Results from Standardized Field Sobriety Tests (SFST) and Roadside Drug Testing)
"Methods Twenty heavy cannabis users (15 males and 5 females; mean age, 24.3 years) participated in a double-blind, placebo-controlled study assessing percentage of impaired individuals on the SFST and the sensitivity of two oral fluid devices. Participants received alcohol doses or
alcohol placebo in combination with 400 ?g/kg body weight THC. We aimed to reach peak blood alcohol concentration values of 0.5 and 0.7 mg/mL.

Prevalence of Marijuana Use Among Full-Time Workers in the US

(Prevalence of Marijuana Use Among Full-Time Workers in the US)
"• An estimated 6.4 percent, or 7.3 million, of full-time workers reported use of marijuana during the past month (Tables 2.2 and 2.3).
"• Adults aged 26 to 34 were only about half as likely as 18- to 25-year-olds to be past month marijuana users (8.0 vs. 15.9 percent). Past month use of marijuana was lower with increasing age (Table 2.2).
"• The prevalence of past month marijuana use was higher for males than females (7.9 vs. 4.3 percent, respectively) (Table 2.2).

Estimated Prevalence of Problem Cannabis Use in Spain

(Estimated Prevalence of Problem Cannabis Use in Spain) "As shown in Table 4.5 above, in 2010, a total of 4.6% of Spain’s students within the 14-18 age range might be involved in a use of drugs which may cause them some type of problem. The prevalence of problem use, calculated by means of the CAST [Cannabis Abuse Screening Test] scale, reveals an upward trend in Spain within the 2006-2010 time period, despite a slight decline in cannabis use having been record for the same period.

Prevalence of Cannabis Use Among Young People in the European Union

(Prevalence of Cannabis Use Among Young People in the European Union) "The most prevalent illicit drug in all ESPAD countries is cannabis. On average, 16 % of the students have used cannabis at least once in their lifetime (Table 7a). The country with the highest prevalence of cannabis use was the Czech Republic (37 %). High prevalence rates (30% or more) were also reported in France, Liechtenstein and Monaco.

Changes In Cannabis Consumer Market Due To Changes In Dutch Coffee Shop Policies

(Changes In Cannabis Consumer Market Due To Changes In Dutch Coffee Shop Policies) "Considerable changes have taken place on the cannabis consumer market in the south of the Netherlands between 1 May (the start of the enforcement of the B- and I-criteria) and October-November 2012:
"• Drug tourists mostly disappeared.
"• The number of visits to coffee shops decreased drastically (Nijkamp & Bieleman, 2013).

Effects of State Medical Marijuana Laws (MMLs) on Youth Marijuana Use

(Effects of State Medical Marijuana Laws (MMLs) on Youth Marijuana Use) "We found no evidence of intermediate-term effects of passage of state MMLs on the prevalence or frequency of adolescent nonmedical marijuana use in the states evaluated, with 2 minor exceptions. From 2003 through 2009, adolescent lifetime prevalence of marijuana use and frequency of daily marijuana use decreased significantly in Montana, as compared with a more modest decrease in lifetime prevalence and an increase in daily frequency observed in Delaware (Ps = .03).

Youth Medical Marijuana Use and Unmet Health Needs

(Youth Medical Marijuana Use and Unmet Health Needs) "Of key importance in the findings are the unmet health needs of these youth. Health issues such as depression, insomnia, and anxiety were significant problems that interfered with these youths' ability to function at school, maintain relationships with family and friends, and feel that they could live a normal life. The level of distress associated with these health concerns, along with the lack of effective interventions by heath care providers and family members appeared to leave them with few alternatives.

Pages